The consistent focus of Dr. Anna Gloyn's research has been using naturally occurring mutations in humans as tools to identity critical regulatory pathways and insights into normal physiology. Her early post-doctoral research led to the identification a new genetic aetiology for permanent and transient neonatal diabetes due to KCNJ11 mutations and resulted in one of the first examples of precision medicine, where the determination of the molecular genetic aetiology lead to improved treatment options for patients. Whilst she was in Oxford, Dr.
Dr. Ann Mullally is a physician-scientist and Division Chief of Hematology. Dr. Mullally received her MD from University College Dublin, completed residency at Johns Hopkins and fellowship in hematology/oncology in the Brigham/Mass General/Dana-Farber program. Prior to moving to Stanford in 2024, Dr. Mullally was a Principal Investigator at Brigham and Women’s Hospital and a clinical faculty member at Dana-Farber Cancer Institute for approximately 10 years. Dr. Mullally is actively involved in all aspects of patient-oriented research.
Dr. Anish Mitra is a neuroscientist and psychiatrist interested in understanding how neural activity in large-scale networks causes mental illness.
Dr. Andrew J. Mannix is an assistant professor of Materials Science and Engineering at Stanford University. He completed his B.S. in Materials Science and Engineering at the University of Illinois at Urbana-Champaign, and his Ph.D. in Materials Science and Engineering at Northwestern University as an NSF GRFP Fellow, where he worked on the growth and atomic-scale characterization of new 2D materials.
